

Heparan sulfate as a regulator of inflammation and immunity

Laura E Collins, Linda Troeberg

Summary sentence: This review summarizes the established and emerging roles of heparan sulfate as an immune regulator through its ability to bind numerous inflammatory ligands both in the microenvironment and on the cell-surface of leukocytes.

Keywords: leukocyte, heparan sulfate, inflammation, chemokines, cytokines

Abbreviations: A1AT, alpha-1 anti-trypsin; APC, antigen-presenting cell; BCR, B cell receptor; DAMP, damage-associated molecular pattern; DC, dendritic cell; ECM, extracellular matrix; EXT, exostosis; EXTL, exostosis-like; FGF-2, fibroblast growth factor 2; GAG, glycosaminoglycan; GLCE, D-glucuronyl C5-epimerase; HEV, high endothelial venule; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan; HS2ST, heparan sulfate 2-O-sulfotransferase; HS3ST, heparan sulfate 3-O-sulfotransferase; HS6ST, heparan sulfate 6-O-sulfotransferase; ICAM-1, intercellular adhesion molecule 1; LPS, lipopolysaccharide; MPO, myeloperoxidase; NDST, N-deacetylase/N-sulfotransferase; PBMC, peripheral blood mononuclear cell; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear neutrophil; SLE, systemic

lupus erythromatous; TGF β R3, transforming growth factor beta receptor 3; TLR4, toll-like receptor 4; WT, wild-type

Abstract: Heparan sulfate is found on the surface of most cell types, as well as in basement membranes and extracellular matrices. Its strong anionic properties and highly variable structure enable this glycosaminoglycan to provide binding sites for numerous protein ligands, including many soluble mediators of the immune system, and may promote or inhibit their activity. The formation of ligand binding sites on heparan sulfate occurs in a tissue- and context-specific fashion through the action of several families of enzymes, most of which have multiple isoforms with subtly different specificities. Changes in the expression levels of these biosynthetic enzymes occur in response to inflammatory stimuli, resulting in structurally different HS and acquisition or loss of binding sites for immune mediators. In this review, we discuss the multiple roles for HS in regulating immune responses, and the evidence for inflammation-associated changes to HS structure.

1 Introduction

Heparan sulfate (HS) is a ubiquitous but highly structurally variable polysaccharide found on cell surfaces and in extracellular matrices, conjugated to one of several types of core protein. Due to its strong anionic properties and the numerous possible combinations of modifications, heparan sulfate can bind to over 400 soluble protein mediators and cell-surface receptors (1), with disparate effects on their activity.

HS plays well-established roles in the formation of chemokine gradients on the vascular endothelium and in regulating the activity of chemokines, cytokines and growth factors through physical sequestration in the matrix and protection from enzymatic proteolysis (recently reviewed in (2)). Here, we briefly outline our current knowledge of the role of HS in these processes, then discuss other currently less appreciated roles for HS in immune regulation, including direct signaling through TLR4, involvement in phagocytosis, and regulating the interaction of inflammatory mediators with their receptors. HS additionally functions in self versus non-self discrimination by the innate immune system through its role as a regulator of the alternative pathway of complement activation, which is reviewed in a number of excellent publications (3-5). Here again, it is the structural variability of HS that enables it to perform various functions in a tissue- and context-specific manner, acting either as an inhibitor of the complement cascade through binding factor H on self surfaces and thus accelerating C3b inactivation, or as an activator through binding the stabilizing factor properdin on apoptotic cells.

Heparan sulfate is found covalently attached to one of several types of core protein, thus forming proteoglycans. The two most abundant types of cell-surface heparan sulfate core protein are the trans-membrane syndecans and the GPI-anchored glypicans, but others such as the secreted proteins perlecan and agrin are also decorated with HS. In addition, some proteins, such as isoform 3 of the hyaluronan receptor (CD44), and betaglycan (TGF β R3) are ‘part-time HSPGs’ in that they bear HS chains in certain tissues or under certain conditions. HS biosynthesis occurs in the Golgi network via the combined actions of more than 25 enzymes, which has been recently and comprehensively reviewed (6). Briefly, biosynthesis begins with the assembly of a tetrasaccharide linkage region at glycosaminoglycan (GAG) attachment sites on the core protein, then the linear HS polysaccharide backbone is elongated by the sequential addition of alternating glucuronic acid and N-acetylglycosamine residues, catalysed by enzymes of the EXT family. Concurrently, HS chains undergo extensive enzymatic modification beginning with N-de-acetylation/N-sulfation, and epimerization of some glucuronic acid residues to iduronic acid by the D-glycuronyl C5-epimerase (GLCE). Sequence complexity is further increased by sulfation at various positions by 2-O-, 3-O-, and 6-O-sulfotransferases that act in a template-independent manner, producing a varied and heterogeneous structure (Figure 1). The requirement for previous modifications to form the substrate for subsequent reactions results in highly sulfated domains flanked by less sulfated transition zones, separated by regions of little or no modification.

How HS structure is regulated is poorly understood, but as most of the modifying enzymes have multiple isoforms with different substrate specificities (7), it is thought that cells may regulate the structure of their HS by altering the relative expression levels of the modifying enzymes (8).

2 HS in the microenvironment regulates the activities of immune cells

HS is an important component of basement membranes and the extracellular matrix, where it immobilizes a variety of ligands. This can have a range of functional consequences including local retention, regulation of receptor interactions, and protection from the actions of proteases, as discussed below and illustrated in Figure 2. In addition, heparan sulfate can itself be a ligand for certain receptors involved in leukocyte recruitment to inflammatory sites.

2.1 HS immobilizes chemokines on vascular and lymphatic endothelium

Circulating blood leukocytes such as monocytes and neutrophils are stimulated to crawl along the endothelium towards inflammatory sites by an immobilized gradient of chemokines, a process called haptotaxis or chemotaxis. More than 40 chemokines have been identified, all of which have been shown or are predicted to bind heparin or heparan sulfate (1). It is thought that a major role of endothelial heparan sulfate is to form a concentration gradient that directs the migration of leukocytes by immobilizing chemokines and preventing them being washed away by the blood flow (Figure 2). This hypothesis is supported by observations that mutant chemokines lacking the ability to bind heparan sulfate fail to recruit leukocytes *in vitro* and *in vivo* (9), (10) (11). Moreover, heparanase-overexpressing mice, which have very short heparan sulfate chains, show impaired neutrophil crawling in response to WT chemokines (12), further demonstrating the importance of the chemokine-GAG interaction.

It has also been observed that many chemokines oligomerize on heparan sulfate and that the ability to form oligomers is required to achieve maximal local concentrations (13). Oligomerization, as well as ability to bind heparan sulfate, appears to be critical for the activity of certain chemokines, as monomeric mutants of RANTES, MIP-1 β and MCP-1 have severely reduced chemotactic activity in vivo when injected IP into mice despite unchanged affinity for their receptors (10).

The variation of HS structure in different tissues may be relevant to chemokine binding; for example, the HS from aortic and venous endothelial cells differs in degree of sulfation (14) which results in the formation of binding sites for chemokines only at post-capillary venules and small veins, where leukocyte emigration occurs, and not in capillaries and arteries (15, 16). Chemokine binding to HS also has some tissue specificity, as demonstrated by the retention of IL-8 in the lungs but not the skin (13). These findings suggest that HS-mediated control of chemokine binding might determine to which sites leukocytes are recruited. Furthermore, it is possible that dynamic regulation of HS during inflammation modulates chemokine gradients and thus chemotaxis. In support of this, staining for HS in high endothelial venules of the lymph node revealed more HS on the basolateral side than the luminal side, and increased deposition of HS on only the basolateral side after stimulation with Total Freund's Adjuvant (17). Thus HS may facilitate formation of a trans-epithelial chemokine gradient that becomes more pronounced during inflammation.

2.2 Endothelial HS as a ligand for leukocyte selectins

In addition to their role in the presentation of chemokines, heparan sulfate proteoglycans are more directly involved in leukocyte recruitment through their capacity to act as ligands for selectins (Figure 2), thus facilitating leukocyte rolling and adhesion (reviewed in (18)). The nature of this interaction has been difficult to unravel since HS is present on both endothelial cells and leukocytes, and selectins are also expressed by both cell types: leukocytes constitutively express L-selectin, whereas endothelial cells upregulate P-selectin upon activation.

In vitro studies using endothelial monolayers in flow chambers to mimic the physiological shear stress of blood vessels have provided evidence of a role for HS in leukocyte recruitment. For example, digesting HS from endothelial monolayers with heparinase III, or adding heparin or soluble HS to the medium, significantly reduces the number of rolling and firmly adhering granulocytes (19), and the total HS deficiency resulting from knockdown of Ext1 in HUVECs prevents normal neutrophil arrest and transendothelial migration (20). Similarly, genetic inactivation of Ndst1 in endothelial cells inhibits granulocyte adhesion to endothelial monolayers and is also associated with decreased binding of recombinant L-selectin (21) suggesting that HS is a physiological ligand for this adhesion molecule. Further supporting this hypothesis, pre-treatment of monocytes with an L-selectin-blocking antibody inhibits their adhesion to endothelial monolayers (22), while the binding of recombinant L-selectin to HEV in tissue sections from various organs is sensitive to heparinase digestion (23).

In vivo studies also imply a major role for the HS-L-selectin interaction in leukocyte recruitment in various inflammatory models. Heparin infusion dramatically inhibits neutrophil infiltration into the peritoneal cavity following thioglycollate injection, and reduced ear thickness and inflammatory cell infiltrate in a contact dermatitis model (24). Importantly, L- and P-selectin doubly-deficient mice showed no further decrease in leukocyte recruitment following heparin treatment, confirming that heparin inhibits inflammation primarily through these two selectins (24). Similarly, the reduced HS sulfation achieved by conditional deletion of *Ndst1* from only endothelial cells and leukocytes results in reduced leukocyte recruitment in models of peritonitis (25), allergen-induced airway remodelling (26, 27), and diabetic (28) and experimental (21) glomerulonephritis. Of particular interest was the observation that chimeric WT mice with *Ndst1*-null bone marrow do not show any defect in thioglycollate-induced lymphocyte homing, whereas KO mice given WT bone marrow show the same reduction in cell infiltrate seen in the mice lacking both endothelial and leukocyte *Ndst1* (25). Conversely, the compensatory increase in N- and 6-O-sulfation resulting from endothelial *Hs2st* deletion leads to increased leukocyte recruitment that is returned to control levels by an L-selectin-blocking antibody (29). These results imply that the crucial interaction is that between the sulfated motifs of endothelial HS and leukocyte L-selectin, whereas leukocyte HS and P-selectin have little effect in this context.

However, while most data indicate that endothelial HS promotes leukocyte adhesion through L-selectin, some studies suggest that HS may have an inhibitory effect on leukocyte attachment. For example, heparinase digestion of microperfused murine venules results in more adherent leukocytes (30) and increased binding of

fluorescently-labelled microspheres coated with anti-ICAM-1 antibody (31), implying that the HS layer might inhibit leukocyte binding by masking endothelial adhesion molecules and making them less accessible to leukocyte integrins (Figure 2). In support of this, intravital microscopy showed that the loss of endothelial glycocalyx following LPS infusion led to increased adhesion of GFP⁺ neutrophils and of anti-ICAM-1 microspheres in WT but not heparanase-null mice (32). These results suggest that heparanase-mediated shedding of endothelial HS in response to a potent inflammatory stimulus may expose more adhesion molecules such as ICAM-1. Thus HS may play two separate roles in leukocyte recruitment: directly by facilitating selectin-mediated leukocyte attachment and rolling, and indirectly through regulating accessibility of other adhesion ligands such as ICAM-1. Further studies are thus required to determine the relative contributions made by HS as a selectin ligand, and as a barrier to ICAM-1 accessibility, over time during the phases of initiation and resolution of an immune response.

Given the multi-faceted role for endothelial HS in leukocyte recruitment, one might expect the structure of HS to be altered in response to inflammatory stimuli or tissue damage in order to regulate immune cell infiltration, and there is evidence that this is indeed the case. For example, endothelial HS sulfation is increased by in vitro stimulation with TGF- β (33), IFN- γ (34), IL-1 β (35), or TNF (36) with associated upregulation of Ndst1, 2, Hs6st1 and 2 (36), and increased ability to bind L-selectin (22) and support the arrest and adherence of leukocytes (19). In vivo, renal ischemia/reperfusion stimulates the formation of binding sites for L-selectin in the interstitial capillaries that are not present in the contralateral control kidney (37). Experimentally induced nephritis is associated with increased expression of highly

sulfated HS domains (38), which are also seen in kidney sections from SLE patients and MRL/*lupr* mice (39) but not healthy controls. Thus it seems likely that dynamically regulating the structure of endothelial HS may be a mechanism to fine-tune cell recruitment during an immune response.

2.3 HS in the ECM regulates activity of cytokines

Cytokine activity is determined by a combination of factors including localization close to the target cell, susceptibility to inactivation by proteolytic cleavage, and ability to interact with high affinity receptors. Numerous cytokines have been demonstrated to bind heparin or HS *in vitro* (1) but the biological consequences of this interaction for cytokine activity have been explored for only a few cytokines. The available data indicate that HS exerts diverse effects on different cytokines, which is hardly surprising given the structural heterogeneity in this functional class of molecules.

Although often described as soluble mediators, cytokines exert their effects locally not systemically and binding to ECM heparan sulfate has been proposed as a mechanism for retaining cytokines close to their site of production and action. For example, endogenous IL-2 is detectable in murine spleen, liver sinusoids, and kidney glomeruli, and staining is absent after treating the sections with heparitinase, but not with chondroitinase (40). Similarly, IFN- γ injected into rats rapidly disappears from the circulation and accumulates in specific tissues including the liver, spleen, and kidney, which is inhibited by co-injection with heparin (41). Thus, heparan sulfate immobilizes certain cytokines in the extracellular space, forming localized reservoirs that may facilitate paracrine signaling (Figure 2).

Whether HS-immobilized chemokines are able to interact with their receptor depends partly on whether the heparan- and receptor-binding sites overlap. Surface plasmon resonance experiments demonstrated that the binding of IFN- γ to its receptor or to HS are mutually exclusive (42), which would imply that immobilized IFN- γ in the matrix cannot signal. However, endothelial monolayers pulsed with IFN- γ stimulate MHC-II upregulation by co-incubated target cells which is abolished by heparinase II treatment (43), suggesting that cell-surface HS might present IFN- γ *in trans* in a signalling-competent manner. Whether HS-bound IFN- γ must dissociate from the matrix to bind its high-affinity receptor, or can bind both simultaneously, remains unresolved. It was recently demonstrated for IL-2 that reservoirs on endothelial and smooth muscle cells of blood vessels are liberated by heparanase in a biologically active form that is competent to stimulate target cell proliferation (44). Thus changes to the matrix that occur during inflammation may release cytokines from ECM reservoirs and enable them to signal.

In addition to regulating availability of soluble cytokine, HS may also influence cytokine activity by controlling their accessibility to proteases (Figure 2). For example, proteolytic cleavage of the C-terminal portion of IFN- γ increases receptor binding if fewer than ten terminal amino acids are removed (42), but binding is decreased by larger deletions (45). Heparin and highly sulfated HS bind IFN- γ at its C-terminus (46), and co-injection of heparin protects IFN- γ from proteolytic degradation *in vivo* (47). Heparin has also been shown to prevent degradation of other cytokines including IL-6 (48) and IL-7 (49) *in vitro*. Thus binding to matrix HS may serve to protect the active form of the cytokine, as well as forming local reservoirs.

Soluble HS fragments released in inflammation may also regulate signalling of some cytokines by promoting their interaction with receptors on target cells. It has been demonstrated that addition of soluble HS to cells that lack detectable levels of this GAG on their surface augments IL-5-induced proliferation (50), and IL-12-stimulated IFN- γ production (51). The mechanism by which soluble HS promotes signalling of these cytokines has not been explored, and the relevance of these observations to inflammatory processes in vivo is not yet clear.

3 Soluble HS directly stimulates immune cells, acting on APCs to control immune responses

HS fragments liberated from the extracellular matrix by enzymes released during inflammation can promote immune activation by signalling through TLR4 and activating APCs.

3.1 Heparan sulfate is degraded in inflammation to become a potent TLR4 ligand.

It has become evident that soluble fragments of HS can signal through toll-like receptor 4 (TLR4), an innate pattern recognition receptor for which the prototypic ligand is bacterial lipopolysaccharide (LPS). Stimulation of DCs with HS fragments induces upregulation of co-stimulatory molecules including CD86 and CD40 and secretion of pro-inflammatory cytokines (52), which is inhibited by TLR4 mutation or the TLR4 antagonist Rs-DPLA (53). These findings suggest that HS is a non-classical

ligand for TLR4 that is capable of signalling to trigger immune activation (Figure 3). Similarly, cardiac fibroblasts stimulated with HS upregulate V-CAM1 and I-CAM1, leading to increased adhesion of PMNs and SMCs, which is completely abolished by the TLR4 inhibitor TAK-242 or by blocking the downstream signalling molecules NFkB or PI3K/Akt (54).

Proliferation of T cells after co-incubation with allogeneic DCs is augmented by soluble HS, but not when the DCs come from mice deficient in TLR4 or its adaptor protein MyD88. However, knockout of these molecules in T cells had no effect (55), and HS treatment of purified T cells stimulated with anti-CD3 in the absence of DCs did not augment proliferation (56), demonstrating that HS indirectly controls lymphocyte activity through regulating APC maturation. Furthermore, murine peritoneal macrophages stimulated with HS upregulate IL-1, IL-6, TNF, and IL-12, and show increased cytotoxicity towards a leukemia cell line (57). *In vivo* evidence for the role of the HS-TLR4 axis in inflammation comes from infusion of soluble HS into the pancreas of mice which results in neutrophil infiltration and increased myeloperoxidase (MPO) activity in WT but not TLR4-null mice (58).

It is thought that the elevated activity of metalloproteases (59), heparanase (60) and other enzymes that occurs in inflammation liberates HS fragments from cell-surface and extracellular matrix HSPGs. These soluble HS fragments could then signal through TLR4 to alert the immune system to tissue damage, thus acting as a damage-associated molecular pattern (DAMP). In support of this hypothesis, endothelial cells with metabolically labelled sulfated GAGs show a decrease in cell-surface HS and an increase in smaller HS fragments in the conditioned medium upon

LPS stimulation (61) or exposure to activated neutrophils, which can be reduced by inhibitors of serine proteases and elastase (62). Furthermore, heparanase treatment of human PBMCs resulted in a reduction of cell-surface HS and an upregulation of pro-inflammatory cytokines similar to that seen by addition of HS fragments, which was abrogated by inhibitors of heparanase or by MyD88 or TLR4 deficiency (63).

In vivo, administration of the serum protease inhibitor alpha-1 anti-trypsin (A1AT) to recipients of allogeneic bone marrow transplants increased survival and lowered serum HS and histological scores. Furthermore, while TLR4 gene deletion conferred some protection from graft-versus-host disease, no further benefit was seen with A1AT treatment (55), indicating that the protective effects of A1AT are mediated through the HS-TLR4 axis. Similarly, injection of elastase into WT mice induced loss of HS from blood vessels, an increase in serum TNF and ultimately death of the mice, whereas TLR4-null mice showed improved survival (64). Collectively, these results suggest a pathway in which fragments of HS produced enzymatically during inflammation signal through TLR4 to further activate the immune system, which may have beneficial or detrimental effects depending on the context.

There is evidence to suggest that the immune system is able to distinguish between endogenous stimuli indicative of tissue damage and exogenous stimuli present as a result of infection, enabling a context-appropriate response to be mounted. For example, macrophages stimulated with LPS or the matrix glycoprotein tenascin-C, which is produced upon tissue injury and also signals through TLR4, resulted in different transcriptional responses and two distinct macrophage

phenotypes (65). LPS-stimulated macrophages had greater collagen-degrading ability and inflammatory cytokine production, whereas tenacin-C treatment induced macrophages to synthesise collagens and other proteins associated with tissue repair. One might thus predict that HS, another endogenous DAMP that signals through TLR4, also stimulates an immune response different to that induced by LPS. In support of this, the kinetics of TLR4 signalling in response to LPS or HS are different, with LPS inducing much more rapid nuclear translocation of NFkB than HS (53) and HS triggering a slower and more sustained increase in intracellular calcium (66). Further studies are required to define how TLR4 signalling induced by endogenous DAMPs such as HS is different to that induced by infection-associated stimuli such as LPS, and whether this results in context-appropriate responses from the immune cell.

4 HS on leukocyte surface regulates their immune and inflammatory functions

Although frequently considered a matrix molecule, HS is expressed on the surface of most cells, including immune cells, in the form of proteoglycans. In addition to regulating receptor interactions both cell autonomously and through ligand presentation to other cells, leukocyte cell-surface HS appears to contribute to specific functions such as phagocytosis. This may be a physiologically relevant mechanism of immune regulation, as the structure of leukocyte HS is altered in response to various inflammatory stimuli.

4.1 Leukocyte HS promotes phagocytic activity

Cell-surface HS is thought to be involved in recognition and uptake of dead cells by phagocytes through exposure of HS binding sites on late apoptotic and

necrotic cells that have lost membrane integrity (Figure 3). For example, FITC-labelled heparin was found to bind to the surface of apoptotic and necrotic cells, but not live cells, and this interaction was inhibitable by heparin but not dermatan or chondroitin sulfates (67). Beads coated with anti-HS antibodies were bound and internalized by epithelial cell lines, but not if the cells had been pre-treated with heparinase III or in the presence of inhibitors of PKC or actin polymerization (68), suggesting that ligation of cell-surface HS is sufficient to stimulate actin-mediated endocytosis in non-professional phagocytes. Similarly, CHO cells and human skin fibroblasts bind and internalize latex beads, and this is strongly reduced by the addition of heparin or soluble HS fragments or by pre-treatment of the cells with heparinase III (69). Additionally, CHO mutant cells lacking the ability to synthesise HS showed defective binding and internalization of the beads, adding further support to an HS-mediated mechanism of phagocytosis. These studies were performed in largely artificial systems with non-professional phagocytes, but there is some evidence that an HS-dependent mechanism of phagocytosis is conserved in a relevant immune setting: human PMNs more efficiently bind and internalize a strain of *H. pylori* that can bind HS than a strain without HS-binding ability, and pre-incubation of the bacteria with heparin inhibited uptake of the HS-binding strain but did not further reduce uptake of the non-HS-binding strain (70) However, further studies are required to determine the relative contribution that HS makes as an endocytic receptor in the presence of canonical phagocytic receptors, antibodies and other opsonins that have an established role in phagocytosis in vivo (71).

4.2 Leukocyte HS regulates responses to inflammatory mediators

HS on the surface of leukocytes appears to play a role in regulating signaling of certain inflammatory mediators through their cell-surface receptors, either by promoting ligand interaction with its receptor, thus acting as a co-receptor, or by inhibiting receptor-ligand interactions, depending on the ligand (Figure 3). For example, the B cell activating factor APRIL, which is essential for IgA class switching in response to mucosal antigens (72), requires HS on the B cell surface for optimal receptor activation and downstream signalling. Heparinase III digestion of B cells strongly reduced APRIL-induced proliferation, IgA production, and NF κ B translocation (73). APRIL can be competed off the B cell surface by heparin, and mutant forms of APRIL without HS-binding ability fail to stimulate IgA production by B cells (74). APRIL does not bind to the surface of Glce^{-/-} B cells, which lack iduronic acid residues, and cannot promote their survival in vitro (75). This may be due to altered downstream modifications by the 2-O- and 6-O-sulfotransferases, whose activity is affected by epimerase inactivation (76).

Another B cell factor, IL-7, also binds heparin and HS, and IL-7-dependent proliferation is inhibited by the addition of heparin (49), suggesting that binding to cell-surface HS promotes IL-7 interacting with its receptor. In support of this, heparitinase treatment of primary B cell precursors diminished surface binding of IL-7 and reduced IL-7-driven proliferation (77).

Interleukin-10 (IL-10) binds both heparin and heparan sulfate, and the addition of soluble fragments of heparan sulfate inhibits the ability of IL-10 to upregulate CD64 and CD16 on monocytes (78). Similarly, IL-10 induced expression of these markers is

inhibited by treatment of monocytes and macrophages with sodium chlorate, which prevents sulfation of GAGs (78), indicating that cell-surface HS promotes the interaction of IL-10 with its receptor. The crystal structure for IL-10 bound to IL-10R1 shows no overlap with the GAG-binding site (79), but there is currently no crystal structure of the ternary complex composed of IL-10 and both receptor subunits. Therefore it remains unclear whether HS acts directly as a co-receptor in the formation of productive IL-10-IL-10R complexes, or simply facilitates IL-10 signaling by preventing diffusion of the cytokine away from the cell surface.

Cells transfected with the splice variant of the hyaluronan receptor (CD44) containing HS attachment sites retain hepatocyte growth factor (HGF) on their cell surface, whereas no binding is seen on cells expressing the isoform of CD44 lacking the HS attachment region (80). The same study showed that ability to bind HGF on the surface resulted in phosphorylation of the HGF receptor tyrosine kinase c-Met, and of ERK-1 and ERK-2. Surface binding and signaling were abolished by heparitinase (but not chondroitinase ABC) treatment or by mutation of the HS-binding domain of HGF, suggesting that HS-mediated capture of HGF on the cell surface facilitates receptor binding and activation. This appears to be a relevant mechanism in B cells since human tonsillar B cells activated by coincident ligation of CD40 and the BCR express a higher molecular weight form of CD44, with concurrent acquisition of HGF-binding ability. Downstream c-Met phosphorylation was abolished by heparitinase treatment of activated B cells (81), indicating that CD44 is decorated with HS following pro-inflammatory stimulation.

However, leukocyte HS may not always promote ligand-receptor interactions, as for certain ligands it acts instead as a barrier and inhibits signalling. Macrophages deficient in HS sulfation through deletion of *Ndst1* show increased responsiveness to IFN- β stimulation and elevated production of pro-inflammatory cytokines and chemokines (82), suggesting that the role of HSPG in IFN- β signaling is to sequester it away from its receptor and thus maintain macrophages in a quiescent state.

4.3 Leukocyte HS regulates cell activation in trans

In addition to these cell-autonomous functions, leukocyte cell-surface HS can also be involved in presentation of growth factors or inflammatory mediators produced by leukocytes to their target cells, as has been demonstrated for FGF-2 (Figure 3). During monocyte-to-macrophage maturation, cells acquire the capacity to bind FGF-2, which is inhibitable by heparin and further augmented by stimulation with IL-1 or LPS (83). The same study showed that activated macrophages augmented the proliferative response of HS-deficient BaF32 cells to low concentrations of FGF-2, which was abolished by heparinase III treatment, indicating that macrophage HS enables trans-presentation of FGF-2 to target cells in a signalling-competent manner. Similarly, activated macrophages increase expression of the CD44v3 isoform of the hyaluronan receptor that contains HS chain attachment sites, and cell lines transfected with this HS-sufficient form of CD44, but not those with the HS-deficient variant, augmented FGF-2-induced proliferation of BaF32 cells (84). Interestingly, both studies found that T cells do not increase expression of CD44v3 or their total HS levels upon mitogenic stimulation, and T cells actually decrease HS expression and lose the ability to bind FGF-2 during consecutive rounds of proliferation (85). These observations suggest that HS-mediated trans-presentation

of growth factors may be a mechanism unique to those cells producing such growth factors upon activation. It remains to be determined whether modulation of HS expression regulates the activity of other HS-binding inflammatory mediators through surface presentation.

4.4 Leukocyte HS structure is altered during inflammation

For leukocyte HS to be considered an active regulator of cell responses, it must itself be altered during the course of an immune response to facilitate changes in inflammatory processes, and there is increasing evidence that such dynamic regulation of HS does occur. B cells from virus-infected mice, or stimulated *in vitro* with the IFN-I-inducer Poly I:C or IFN- β , show increased surface expression of HS and augmented APRIL-induced production of IgA (86). Similarly, stimulation with phorbol 12-myristate 13-acetate (PMA) or ligation of CD40 results in an increase in HS on the B cell surface and a switch to the higher molecular weight form of CD44 that has HS chains (81). HS structure may also be regulated during B cell development, as ligation of the pre-BCR induces upregulation of numerous HS-associated genes including *Hs3st1* (87). Furthermore, microarray analyses of different B cell subsets show greater expression of HS biosynthetic enzymes in plasma cells than memory B cells (88), suggesting activation is associated with an increase in cell-surface HS.

Differential expression of HS is also a feature of macrophage subsets, as human monocyte-derived macrophages polarized to an anti-inflammatory reparative phenotype display greater upregulation of sulfotransferases than pro-inflammatory macrophages, resulting in more cell-surface HS with a higher degree of 2-O-sulfation

(89). Importantly, this differential expression of HS was shown to have functional consequences: reparative macrophages bound more FGF-2 and augmented FGF-2-dependent proliferation of a target cell line, consistent with the requirement of 2-O-sulfation for FGF-2 binding (90). This suggests that the expression of more highly sulfated HS in reparative macrophages may be important for their role in the resolution of inflammation. Various other stimuli have been reported to affect HS structure on macrophages, such as LPS and TNF which induce upregulation of HS3ST3B and consequently an increase in 3-O-sulfation (91), and hypoxia which significantly reduces expression of biosynthetic enzymes and total HS content (92).

Interestingly, macrophages from the synovial fluid of RA and SLE patients show greater FGF-2 binding than blood monocytes (83), and CD44-HS splice variants were highly expressed in RA but not OA joints and co-localized with staining for macrophage markers and FGF-2 (84). These findings suggest that excessive growth factor activity seen during chronic inflammation may be partly due to aberrant regulation of leukocyte HS sulfation.

5. Concluding remarks

It is becoming increasingly apparent that HS has multiple roles in immune regulation and signalling during inflammation, both in the microenvironment and on the cell-surface of leukocytes. Soluble HS fragments also have signalling properties and may serve as indicators of tissue damage. Further studies are required for a better understanding of the changes in HS expression that occur during inflammation and the structural requirements for binding and regulation of immune mediators. Understanding these structure-function relationships will be essential for the

development of therapeutics that interfere these processes to combat immunopathology, which might take the form of synthetic HS oligosaccharides or HS-specific antibodies.

Authorship: Laura E Collins conceived the idea and wrote the manuscript. Linda Troeberg edited.

Acknowledgements: The authors are supported by the Kennedy Trust for Rheumatology Research. Linda Troeberg is funded in part by Arthritis Research UK (No. 20887).

Conflict of interest disclosure: The authors declare no conflict of interest.

References

1. Ori, A., M. C. Wilkinson, and D. G. Fernig. 2011. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. *J Biol Chem* 286: 19892-19904.
2. Proudfoot, A. E. I., Z. Johnson, P. Bonvin, and T. M. Handel. 2017. Glycosaminoglycan Interactions with Chemokines Add Complexity to a Complex System. *Pharmaceuticals (Basel)* 10.
3. Borza, D. B. 2017. Glomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activation. *Matrix Biol* 57-58: 299-310.
4. Langford-Smith, A., A. J. Day, P. N. Bishop, and S. J. Clark. 2015. Complementing the Sugar Code: Role of GAGs and Sialic Acid in Complement Regulation. *Front Immunol* 6: 25.
5. Meri, S. 2016. Self-nonsel discrimination by the complement system. *FEBS Lett* 590: 2418-2434.
6. Hull, E. E., M. R. Montgomery, and K. J. Leyva. 2017. Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers. *Int J Mol Sci* 18.
7. Liu, J., and L. C. Pedersen. 2007. Anticoagulant heparan sulfate: structural specificity and biosynthesis. *Appl Microbiol Biotechnol* 74: 263-272.
8. Zhang, X., F. Wang, and J. Sheng. 2016. "Coding" and "Decoding": hypothesis for the regulatory mechanism involved in heparan sulfate biosynthesis. *Carbohydr Res* 428: 1-7.

9. Weber, M., R. Hauschild, J. Schwarz, C. Moussion, I. de Vries, D. F. Legler, S. A. Luther, T. Bollenbach, and M. Sixt. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients. *Science* 339: 328-332.
10. Proudfoot, A. E., T. M. Handel, Z. Johnson, E. K. Lau, P. LiWang, I. Clark-Lewis, F. Borlat, T. N. Wells, and M. H. Kosco-Vilbois. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. *Proc Natl Acad Sci U S A* 100: 1885-1890.
11. Severin, I. C., J. P. Gaudry, Z. Johnson, A. Kungl, A. Jansma, B. Gesslbauer, B. Mulloy, C. Power, A. E. Proudfoot, and T. Handel. 2010. Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans. *J Biol Chem* 285: 17713-17724.
12. Massena, S., G. Christoffersson, E. Hjertstrom, E. Zcharia, I. Vlodavsky, N. Ausmees, C. Rolny, J. P. Li, and M. Phillipson. 2010. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. *Blood* 116: 1924-1931.
13. Frevert, C. W., R. B. Goodman, M. G. Kinsella, O. Kajikawa, K. Ballman, I. Clark-Lewis, A. E. Proudfoot, T. N. Wells, and T. R. Martin. 2002. Tissue-specific mechanisms control the retention of IL-8 in lungs and skin. *J Immunol* 168: 3550-3556.
14. Lowe-Krentz, L. J., and J. G. Joyce. 1991. Venous and aortic porcine endothelial cells cultured under standardized conditions synthesize heparan sulfate chains which differ in charge. *Anal Biochem* 193: 155-163.
15. Rot, A. 1992. Binding of neutrophil attractant/activation protein-1 (interleukin 8) to resident dermal cells. *Cytokine* 4: 347-352.
16. Hub, E., and A. Rot. 1998. Binding of RANTES, MCP-1, MCP-3, and MIP-1alpha to cells in human skin. *Am J Pathol* 152: 749-757.
17. Stoler-Barak, L., C. Moussion, E. Shezen, M. Hatzav, M. Sixt, and R. Alon. 2014. Blood vessels pattern heparan sulfate gradients between their apical and basolateral aspects. *PLoS One* 9: e85699.
18. Parish, C. R. 2006. The role of heparan sulphate in inflammation. *Nat Rev Immunol* 6: 633-643.
19. Rops, A. L., C. W. Jacobs, P. C. Linssen, J. B. Boezeman, J. F. Lensen, T. J. Wijnhoven, L. P. van den Heuvel, T. H. van Kuppevelt, J. van der Vlag, and J. H. Berden. 2007. Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes. *Nephrol Dial Transplant* 22: 1070-1077.
20. Stoler-Barak, L., S. Barzilai, A. Zauberman, and R. Alon. 2014. Transendothelial migration of effector T cells across inflamed endothelial barriers does not require heparan sulfate proteoglycans. *Int Immunol* 26: 315-324.
21. Rops, A. L., M. A. Loeven, J. J. van Gemst, I. Eversen, X. M. Van Wijk, H. B. Dijkman, T. H. van Kuppevelt, J. H. Berden, T. J. Rabelink, J. D. Esko, and J. van der Vlag. 2014. Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. *Kidney Int* 86: 932-942.
22. Giuffre, L., A. S. Cordey, N. Monai, Y. Tardy, M. Schapira, and O. Spertini. 1997. Monocyte adhesion to activated aortic endothelium: role of L-selectin and heparan sulfate proteoglycans. *J Cell Biol* 136: 945-956.
23. Celie, J. W., E. D. Keuning, R. H. Beelen, A. M. Drager, S. Zweegman, F. L. Kessler, R. Soininen, and J. van den Born. 2005. Identification of L-selectin

- binding heparan sulfates attached to collagen type XVIII. *J Biol Chem* 280: 26965-26973.
24. Wang, L., J. R. Brown, A. Varki, and J. D. Esko. 2002. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. *J Clin Invest* 110: 127-136.
 25. Wang, L., M. Fuster, P. Sriramarao, and J. D. Esko. 2005. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. *Nat Immunol* 6: 902-910.
 26. Ge, X. N., S. G. Ha, A. Rao, Y. G. Greenberg, M. N. Rushdi, J. D. Esko, S. P. Rao, and P. Sriramarao. 2014. Endothelial and leukocyte heparan sulfates regulate the development of allergen-induced airway remodeling in a mouse model. *Glycobiology* 24: 715-727.
 27. Zuberi, R. I., X. N. Ge, S. Jiang, N. S. Bahaie, B. N. Kang, R. M. Hosseinkhani, E. M. Frenzel, M. M. Fuster, J. D. Esko, S. P. Rao, and P. Sriramarao. 2009. Deficiency of endothelial heparan sulfates attenuates allergic airway inflammation. *J Immunol* 183: 3971-3979.
 28. Talsma, D. T., K. Katta, M. A. B. Ettema, B. Kel, M. Kusche-Gullberg, M. R. Daha, C. A. Stegeman, J. van den Born, and L. Wang. 2018. Endothelial heparan sulfate deficiency reduces inflammation and fibrosis in murine diabetic nephropathy. *Lab Invest*.
 29. Axelsson, J., D. Xu, B. N. Kang, J. K. Nussbacher, T. M. Handel, K. Ley, P. Sriramarao, and J. D. Esko. 2012. Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. *Blood* 120: 1742-1751.
 30. Constantinescu, A. A., H. Vink, and J. A. Spaan. 2003. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. *Arterioscler Thromb Vasc Biol* 23: 1541-1547.
 31. Mulivor, A. W., and H. H. Lipowsky. 2002. Role of glycocalyx in leukocyte-endothelial cell adhesion. *Am J Physiol Heart Circ Physiol* 283: H1282-1291.
 32. Schmidt, E. P., Y. Yang, W. J. Janssen, A. Gandjeva, M. J. Perez, L. Barthel, R. L. Zemans, J. C. Bowman, D. E. Koyanagi, Z. X. Yunt, L. P. Smith, S. S. Cheng, K. H. Overdier, K. R. Thompson, M. W. Geraci, I. S. Douglas, D. B. Pearce, and R. M. Tudor. 2012. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. *Nat Med* 18: 1217-1223.
 33. Kasinath, B. S. 1993. Glomerular endothelial cell proteoglycans--regulation by TGF-beta 1. *Arch Biochem Biophys* 305: 370-377.
 34. Carter, N. M., S. Ali, and J. A. Kirby. 2003. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. *J Cell Sci* 116: 3591-3600.
 35. Sorensson, J., A. Bjornson, M. Ohlson, B. J. Ballermann, and B. Haraldsson. 2003. Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. *Am J Physiol Renal Physiol* 284: F373-380.
 36. Rops, A. L., M. J. van den Hoven, M. M. Baselmans, J. F. Lensen, T. J. Wijnhoven, L. P. van den Heuvel, T. H. van Kuppevelt, J. H. Berden, and J. van der Vlag. 2008. Heparan sulfate domains on cultured activated glomerular endothelial cells mediate leukocyte trafficking. *Kidney Int* 73: 52-62.
 37. Celie, J. W., N. W. Rutjes, E. D. Keuning, R. Soininen, R. Heljasvaara, T. Pihlajaniemi, A. M. Drager, S. Zweegman, F. L. Kessler, R. H. Beelen, S.

- Florquin, J. Aten, and J. van den Born. 2007. Subendothelial heparan sulfate proteoglycans become major L-selectin and monocyte chemoattractant protein-1 ligands upon renal ischemia/reperfusion. *Am J Pathol* 170: 1865-1878.
38. Rops, A. L., M. Gotte, M. H. Baselmans, M. J. van den Hoven, E. J. Steenbergen, J. F. Lensen, T. J. Wijnhoven, F. Cevikbas, L. P. van den Heuvel, T. H. van Kuppevelt, J. H. Berden, and J. van der Vlag. 2007. Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. *Kidney Int* 72: 1204-1215.
 39. Rops, A. L., M. J. van den Hoven, M. A. Bakker, J. F. Lensen, T. J. Wijnhoven, L. P. van den Heuvel, T. H. van Kuppevelt, J. van der Vlag, and J. H. Berden. 2007. Expression of glomerular heparan sulphate domains in murine and human lupus nephritis. *Nephrol Dial Transplant* 22: 1891-1902.
 40. Wrenshall, L. E., and J. L. Platt. 1999. Regulation of T cell homeostasis by heparan sulfate-bound IL-2. *J Immunol* 163: 3793-3800.
 41. Lortat-Jacob, H., C. Brisson, S. Guerret, and G. Morel. 1996. Non-receptor-mediated tissue localization of human interferon-gamma: role of heparan sulfate/heparin-like molecules. *Cytokine* 8: 557-566.
 42. Sadir, R., E. Forest, and H. Lortat-Jacob. 1998. The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation. *J Biol Chem* 273: 10919-10925.
 43. Fernandez-Botran, R., J. Yan, and D. E. Justus. 1999. Binding of interferon gamma by glycosaminoglycans: a strategy for localization and/or inhibition of its activity. *Cytokine* 11: 313-325.
 44. Miller, J. D., S. E. Clabaugh, D. R. Smith, R. B. Stevens, and L. E. Wrenshall. 2012. Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase. *Immunol Cell Biol* 90: 159-167.
 45. Leinikki, P. O., J. Calderon, M. H. Luquette, and R. D. Schreiber. 1987. Reduced receptor binding by a human interferon-gamma fragment lacking 11 carboxyl-terminal amino acids. *J Immunol* 139: 3360-3366.
 46. Lortat-Jacob, H., and J. A. Grimaud. 1991. Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. *FEBS Lett* 280: 152-154.
 47. Lortat-Jacob, H., F. Baltzer, and J. A. Grimaud. 1996. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. *J Biol Chem* 271: 16139-16143.
 48. Mummery, R. S., and C. C. Rider. 2000. Characterization of the heparin-binding properties of IL-6. *J Immunol* 165: 5671-5679.
 49. Clarke, D., O. Katoh, R. V. Gibbs, S. D. Griffiths, and M. Y. Gordon. 1995. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. *Cytokine* 7: 325-330.
 50. Lipscombe, R. J., A. M. Nakhoul, C. J. Sanderson, and D. R. Coombe. 1998. Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix. *J Leukoc Biol* 63: 342-350.
 51. Jayanthi, S., B. P. Koppolu, K. G. Nguyen, S. G. Smith, B. K. Felber, T. K. S. Kumar, and D. A. Zaharoff. 2017. Modulation of Interleukin-12 activity in the presence of heparin. *Sci Rep* 7: 5360.

52. Kodaira, Y., S. K. Nair, L. E. Wrenshall, E. Gilboa, and J. L. Platt. 2000. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. *J Immunol* 165: 1599-1604.
53. Johnson, G. B., G. J. Brunn, Y. Kodaira, and J. L. Platt. 2002. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. *J Immunol* 168: 5233-5239.
54. Olivares-Silva, F., R. Landaeta, P. Aranguiz, S. Bolivar, C. Humeres, R. Anfossi, R. Vivar, P. Boza, C. Munoz, V. Pardo-Jimenez, C. Peiro, C. F. Sanchez-Ferrer, and G. Diaz-Araya. 2018. Heparan sulfate potentiates leukocyte adhesion on cardiac fibroblast by enhancing Vcam-1 and Icam-1 expression. *Biochim Biophys Acta* 1864: 831-842.
55. Brennan, T. V., L. Lin, X. Huang, D. M. Cardona, Z. Li, K. Dredge, N. J. Chao, and Y. Yang. 2012. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. *Blood* 120: 2899-2908.
56. Wrenshall, L. E., F. B. Cerra, A. Carlson, F. H. Bach, and J. L. Platt. 1991. Regulation of murine splenocyte responses by heparan sulfate. *J Immunol* 147: 455-459.
57. Wrenshall, L. E., R. B. Stevens, F. B. Cerra, and J. L. Platt. 1999. Modulation of macrophage and B cell function by glycosaminoglycans. *J Leukoc Biol* 66: 391-400.
58. Akbarshahi, H., J. B. Axelsson, K. Said, A. Malmstrom, H. Fischer, and R. Andersson. 2011. TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. *J Transl Med* 9: 219.
59. Nissinen, L., and V. M. Kahari. 2014. Matrix metalloproteinases in inflammation. *Biochim Biophys Acta* 1840: 2571-2580.
60. Meirovitz, A., R. Goldberg, A. Binder, A. M. Rubinstein, E. Hermano, and M. Elkin. 2013. Heparanase in inflammation and inflammation-associated cancer. *FEBS J* 280: 2307-2319.
61. Geller, R. L., N. S. Ihrcke, J. Maines, B. J. Lindman, and J. L. Platt. 1993. Loss of heparan sulfate proteoglycan as a manifestation of cellular immunity in vivo and in vitro. *Transplant Proc* 25: 144-145.
62. Key, N. S., J. L. Platt, and G. M. Vercellotti. 1992. Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. *Arterioscler Thromb* 12: 836-842.
63. Goodall, K. J., I. K. Poon, S. Phipps, and M. D. Hulett. 2014. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. *PLoS One* 9: e109596.
64. Johnson, G. B., G. J. Brunn, and J. L. Platt. 2004. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. *J Immunol* 172: 20-24.
65. Piccinini, A. M., L. Zuliani-Alvarez, J. M. Lim, and K. S. Midwood. 2016. Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages. *Sci Signal* 9: ra86.
66. Wrenshall, L. E., F. B. Cerra, R. K. Singh, and J. L. Platt. 1995. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. *J Immunol* 154: 871-880.
67. Gebaska, M. A., I. Titley, H. F. Paterson, R. M. Morilla, D. C. Davies, A. M. Gruszka-Westwood, V. V. Kakkar, S. Eccles, and M. F. Scully. 2002. High-affinity binding sites for heparin generated on leukocytes during apoptosis

- arise from nuclear structures segregated during cell death. *Blood* 99: 2221-2227.
68. Dehio, C., E. Freissler, C. Lanz, O. G. Gomez-Duarte, G. David, and T. F. Meyer. 1998. Ligation of cell surface heparan sulfate proteoglycans by antibody-coated beads stimulates phagocytic uptake into epithelial cells: a model for cellular invasion by *Neisseria gonorrhoeae*. *Exp Cell Res* 242: 528-539.
 69. Fukasawa, M., F. Sekine, M. Miura, M. Nishijima, and K. Hanada. 1997. Involvement of heparan sulfate proteoglycans in the binding step for phagocytosis of latex beads by Chinese hamster ovary cells. *Exp Cell Res* 230: 154-162.
 70. Chmiela, M., B. Paziak-Domanska, and T. Wadstrom. 1995. Attachment, ingestion and intracellular killing of *Helicobacter pylori* by human peripheral blood mononuclear leukocytes and mouse peritoneal inflammatory macrophages. *FEMS Immunol Med Microbiol* 10: 307-316.
 71. Stuart, L. M., and R. A. Ezekowitz. 2005. Phagocytosis: elegant complexity. *Immunity* 22: 539-550.
 72. Castigli, E., S. Scott, F. Dedeoglu, P. Bryce, H. Jabara, A. K. Bhan, E. Mizoguchi, and R. S. Geha. 2004. Impaired IgA class switching in APRIL-deficient mice. *Proc Natl Acad Sci U S A* 101: 3903-3908.
 73. Sakurai, D., H. Hase, Y. Kanno, H. Kojima, K. Okumura, and T. Kobata. 2007. TACI regulates IgA production by APRIL in collaboration with HSPG. *Blood* 109: 2961-2967.
 74. Kimberley, F. C., L. van Bostelen, K. Cameron, G. Hardenberg, J. A. Marquart, M. Hahne, and J. P. Medema. 2009. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. *FASEB J* 23: 1584-1595.
 75. Reijmers, R. M., R. W. Groen, A. Kuil, K. Weijer, F. C. Kimberley, J. P. Medema, T. H. van Kuppevelt, J. P. Li, M. Spaargaren, and S. T. Pals. 2011. Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. *Blood* 117: 6162-6171.
 76. Townley, R. A., and H. E. Bulow. 2011. Genetic analysis of the heparan modification network in *Caenorhabditis elegans*. *J Biol Chem* 286: 16824-16831.
 77. Borghesi, L. A., Y. Yamashita, and P. W. Kincade. 1999. Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis. *Blood* 93: 140-148.
 78. Salek-Ardakani, S., J. R. Arrand, D. Shaw, and M. Mackett. 2000. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. *Blood* 96: 1879-1888.
 79. Josephson, K., N. J. Logsdon, and M. R. Walter. 2001. Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. *Immunity* 15: 35-46.
 80. van der Voort, R., T. E. Taher, V. J. Wielenga, M. Spaargaren, R. Prevo, L. Smit, G. David, G. Hartmann, E. Gherardi, and S. T. Pals. 1999. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. *J Biol Chem* 274: 6499-6506.
 81. van der Voort, R., R. M. Keehnen, E. A. Beuling, M. Spaargaren, and S. T. Pals. 2000. Regulation of cytokine signaling by B cell antigen receptor and

- CD40-controlled expression of heparan sulfate proteoglycans. *J Exp Med* 192: 1115-1124.
82. Gordts, P. L., E. M. Foley, R. Lawrence, R. Sinha, C. Lameda-Diaz, L. Deng, R. Nock, C. K. Glass, A. Erbilgin, A. J. Lusis, J. L. Witztum, and J. D. Esko. 2014. Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. *Cell Metab* 20: 813-826.
 83. Clasper, S., S. Vekemans, M. Fiore, M. Plebanski, P. Wordsworth, G. David, and D. G. Jackson. 1999. Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. *J Biol Chem* 274: 24113-24123.
 84. Jones, M., L. Tussey, N. Athanasou, and D. G. Jackson. 2000. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. *J Biol Chem* 275: 7964-7974.
 85. Garner, O. B., Y. Yamaguchi, J. D. Esko, and V. Videm. 2008. Small changes in lymphocyte development and activation in mice through tissue-specific alteration of heparan sulphate. *Immunology* 125: 420-429.
 86. Jarousse, N., D. L. Trujillo, S. Wilcox-Adelman, and L. Coscoy. 2011. Virally-induced upregulation of heparan sulfate on B cells via the action of type I IFN. *J Immunol* 187: 5540-5547.
 87. Schebesta, M., P. L. Pfeffer, and M. Busslinger. 2002. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. *Immunity* 17: 473-485.
 88. Bret, C., D. Hose, T. Reme, A. C. Sprynski, K. Mahtouk, J. F. Schved, P. Quittet, J. F. Rossi, H. Goldschmidt, and B. Klein. 2009. Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. *Br J Haematol* 145: 350-368.
 89. Martinez, P., A. Denys, M. Delos, A. S. Sikora, M. Carpentier, S. Julien, J. Pestel, and F. Allain. 2015. Macrophage polarization alters the expression and sulfation pattern of glycosaminoglycans. *Glycobiology* 25: 502-513.
 90. Rahmoune, H., H. L. Chen, J. T. Gallagher, P. S. Rudland, and D. G. Fernig. 1998. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. *J Biol Chem* 273: 7303-7310.
 91. Sikora, A. S., M. Delos, P. Martinez, M. Carpentier, F. Allain, and A. Denys. 2016. Regulation of the Expression of Heparan Sulfate 3-O-Sulfotransferase 3B (HS3ST3B) by Inflammatory Stimuli in Human Monocytes. *J Cell Biochem* 117: 1529-1542.
 92. Asplund, A., G. Ostergren-Lunden, G. Camejo, P. Stillemark-Billton, and G. Bondjers. 2009. Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis. *J Leukoc Biol* 86: 381-388.
 93. Ruppert, R., E. Hoffmann, and W. Sebald. 1996. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. *Eur J Biochem* 237: 295-302.

94. Sampath, T. K., N. Muthukumaran, and A. H. Reddi. 1987. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. *Proc Natl Acad Sci U S A* 84: 7109-7113.
95. Ohkawara, B., S. Iemura, P. ten Dijke, and N. Ueno. 2002. Action range of BMP is defined by its N-terminal basic amino acid core. *Curr Biol* 12: 205-209.
96. Irie, A., H. Habuchi, K. Kimata, and Y. Sanai. 2003. Heparan sulfate is required for bone morphogenetic protein-7 signaling. *Biochem Biophys Res Commun* 308: 858-865.
97. Brigstock, D. R., C. L. Steffen, G. Y. Kim, R. K. Vegunta, J. R. Diehl, and P. A. Harding. 1997. Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. *J Biol Chem* 272: 20275-20282.
98. Kiefer, P., G. Peters, and C. Dickson. 1991. The Int-2/Fgf-3 oncogene product is secreted and associates with extracellular matrix: implications for cell transformation. *Mol Cell Biol* 11: 5929-5936.
99. Bellosta, P., A. Iwahori, A. N. Plotnikov, A. V. Eliseenkova, C. Basilico, and M. Mohammadi. 2001. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. *Mol Cell Biol* 21: 5946-5957.
100. Clements, D. A., J. K. Wang, C. A. Dionne, and M. Goldfarb. 1993. Activation of fibroblast growth factor (FGF) receptors by recombinant human FGF-5. *Oncogene* 8: 1311-1316.
101. Pizette, S., M. Batoz, H. Prats, D. Birnbaum, and F. Coulier. 1991. Production and functional characterization of human recombinant FGF-6 protein. *Cell Growth Differ* 2: 561-566.
102. Loo, B. M., and M. Salmivirta. 2002. Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b. *J Biol Chem* 277: 32616-32623.
103. Hecht, H. J., R. Adar, B. Hofmann, O. Bogin, H. Weich, and A. Yayon. 2001. Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces. *Acta Crystallogr D Biol Crystallogr* 57: 378-384.
104. Igarashi, M., P. W. Finch, and S. A. Aaronson. 1998. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). *J Biol Chem* 273: 13230-13235.
105. Olsen, S. K., M. Garbi, N. Zampieri, A. V. Eliseenkova, D. M. Ornitz, M. Goldfarb, and M. Mohammadi. 2003. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. *J Biol Chem* 278: 34226-34236.
106. Asada, M., M. Shinomiya, M. Suzuki, E. Honda, R. Sugimoto, M. Ikekita, and T. Imamura. 2009. Glycosaminoglycan affinity of the complete fibroblast growth factor family. *Biochim Biophys Acta* 1790: 40-48.
107. Thompson, L. D., M. W. Pantoliano, and B. A. Springer. 1994. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. *Biochemistry* 33: 3831-3840.

108. Fan, H., S. N. Vitharana, T. Chen, D. O'Keefe, and C. R. Middaugh. 2007. Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20. *Mol Pharm* 4: 232-240.
109. Thompson, S. A., S. Higashiyama, K. Wood, N. S. Pollitt, D. Damm, G. McEnroe, B. Garrick, N. Ashton, K. Lau, N. Hancock, and et al. 1994. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. *J Biol Chem* 269: 2541-2549.
110. Lustig, F., J. Hoebeke, G. Ostergren-Lunden, F. Velge-Roussel, G. Bondjers, U. Olsson, U. Ruetschi, and G. Fager. 1996. Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans. *Biochemistry* 35: 12077-12085.
111. Schilling, D., I. J. Reid, A. Hujer, D. Morgan, E. Demoll, P. Bummer, R. A. Fenstermaker, and D. M. Kaetzel. 1998. Loop III region of platelet-derived growth factor (PDGF) B-chain mediates binding to PDGF receptors and heparin. *Biochem J* 333 (Pt 3): 637-644.
112. Krilleke, D., A. DeErkenez, W. Schubert, I. Giri, G. S. Robinson, Y. S. Ng, and D. T. Shima. 2007. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. *J Biol Chem* 282: 28045-28056.
113. Makinen, T., B. Olofsson, T. Karpanen, U. Hellman, S. Soker, M. Klagsbrun, U. Eriksson, and K. Alitalo. 1999. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. *J Biol Chem* 274: 21217-21222.
114. Lyon, M., G. Rushton, and J. T. Gallagher. 1997. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. *J Biol Chem* 272: 18000-18006.
115. Sue, S. C., J. Y. Chen, S. C. Lee, W. G. Wu, and T. H. Huang. 2004. Solution structure and heparin interaction of human hepatoma-derived growth factor. *J Mol Biol* 343: 1365-1377.
116. Holmes, O., S. Pillozzi, J. A. Deakin, F. Carafoli, L. Kemp, P. J. Butler, M. Lyon, and E. Gherardi. 2007. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. *J Mol Biol* 367: 395-408.
117. Lau, E. K., C. D. Paavola, Z. Johnson, J. P. Gaudry, E. Geretti, F. Borlat, A. J. Kungl, A. E. Proudfoot, and T. M. Handel. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. *J Biol Chem* 279: 22294-22305.
118. Koopmann, W., and M. S. Krangel. 1997. Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1alpha. *J Biol Chem* 272: 10103-10109.
119. Koopmann, W., C. Ediriwickrema, and M. S. Krangel. 1999. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. *J Immunol* 163: 2120-2127.
120. Proudfoot, A. E., S. Fritchley, F. Borlat, J. P. Shaw, F. Vilbois, C. Zwahlen, A. Trkola, D. Marchant, P. R. Clapham, and T. N. Wells. 2001. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. *J Biol Chem* 276: 10620-10626.
121. Kuschert, G. S., F. Coulin, C. A. Power, A. E. Proudfoot, R. E. Hubbard, A. J. Hoogewerf, and T. N. Wells. 1999. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. *Biochemistry* 38: 12959-12968.

122. Yu, Y., M. D. Sweeney, O. M. Saad, S. E. Crown, A. R. Hsu, T. M. Handel, and J. A. Leary. 2005. Chemokine-glycosaminoglycan binding: specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry. *J Biol Chem* 280: 32200-32208.
123. Ellyard, J. I., L. Simson, A. Bezos, K. Johnston, C. Freeman, and C. R. Parish. 2007. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. *J Biol Chem* 282: 15238-15247.
124. Hoover, D. M., L. S. Mizoue, T. M. Handel, and J. Lubkowski. 2000. The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. *J Biol Chem* 275: 23187-23193.
125. Escher, S. E., U. Forssmann, A. Frimpong-Boateng, K. Adermann, J. Vakili, H. Sticht, and M. Detheux. 2004. Functional analysis of chemically synthesized derivatives of the human CC chemokine CCL15/HCC-2, a high affinity CCR1 ligand. *J Pept Res* 63: 36-47.
126. Patel, D. D., W. Koopmann, T. Imai, L. P. Whichard, O. Yoshie, and M. S. Krangel. 2001. Chemokines have diverse abilities to form solid phase gradients. *Clin Immunol* 99: 43-52.
127. de Paz, J. L., E. A. Moseman, C. Noti, L. Polito, U. H. von Andrian, and P. H. Seeberger. 2007. Profiling heparin-chemokine interactions using synthetic tools. *ACS Chem Biol* 2: 735-744.
128. Godiska, R., D. Chantry, C. J. Raport, S. Sozzani, P. Allavena, D. Leviten, A. Mantovani, and P. W. Gray. 1997. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. *J Exp Med* 185: 1595-1604.
129. Rajarathnam, K., Y. Li, T. Rohrer, and R. Gentz. 2001. Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine. *J Biol Chem* 276: 4909-4916.
130. Culley, F. J., E. J. Fadlon, A. Kirchem, T. J. Williams, P. J. Jose, and J. E. Pease. 2003. Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. *Eur J Immunol* 33: 1302-1310.
131. Witt, D. P., and A. D. Lander. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. *Curr Biol* 4: 394-400.
132. Wolpe, S. D., B. Sherry, D. Juers, G. Davatellis, R. W. Yurt, and A. Cerami. 1989. Identification and characterization of macrophage inflammatory protein 2. *Proc Natl Acad Sci U S A* 86: 612-616.
133. Ori, A., P. Free, J. Courty, M. C. Wilkinson, and D. G. Fernig. 2009. Identification of heparin-binding sites in proteins by selective labeling. *Mol Cell Proteomics* 8: 2256-2265.
134. Teixeira, M. G., K. J. Austin, D. J. Perry, V. D. Dooley, G. A. Johnson, B. R. Francis, and T. R. Hansen. 1997. Bovine granulocyte chemotactic protein-2 is secreted by the endometrium in response to interferon-tau (IFN-tau). *Endocrine* 6: 31-37.
135. Campanella, G. S., E. M. Lee, J. Sun, and A. D. Luster. 2003. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). *J Biol Chem* 278: 17066-17074.
136. Cox, J. H., R. A. Dean, C. R. Roberts, and C. M. Overall. 2008. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. *J Biol Chem* 283: 19389-19399.

137. Najjam, S., B. Mulloy, J. Theze, M. Gordon, R. Gibbs, and C. C. Rider. 1998. Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites. *Glycobiology* 8: 509-516.
138. Gupta, P., T. R. Oegema, Jr., J. J. Brazil, A. Z. Dudek, A. Slungaard, and C. M. Verfaillie. 2000. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. *Blood* 95: 147-155.
139. Lortat-Jacob, H., P. Garrone, J. Banchemare, and J. A. Grimaud. 1997. Human interleukin 4 is a glycosaminoglycan-binding protein. *Cytokine* 9: 101-105.
140. Hasan, M., S. Najjam, M. Y. Gordon, R. V. Gibbs, and C. C. Rider. 1999. IL-12 is a heparin-binding cytokine. *J Immunol* 162: 1064-1070.
141. Kenig, M., V. Gaberc-Porekar, I. Fonda, and V. Menart. 2008. Identification of the heparin-binding domain of TNF-alpha and its use for efficient TNF-alpha purification by heparin-Sepharose affinity chromatography. *J Chromatogr B Analyt Technol Biomed Life Sci* 867: 119-125.
142. Spencer, J. L., P. J. Stone, and M. A. Nugent. 2006. New insights into the inhibition of human neutrophil elastase by heparin. *Biochemistry* 45: 9104-9120.
143. Kan, M., F. Wang, J. Xu, J. W. Crabb, J. Hou, and W. L. McKeehan. 1993. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. *Science* 259: 1918-1921.
144. Powell, A. K., D. G. Fernig, and J. E. Turnbull. 2002. Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate. Implications for dynamic assembly of a ternary signaling complex. *J Biol Chem* 277: 28554-28563.
145. Olsen, S. K., O. A. Ibrahim, A. Raucchi, F. Zhang, A. V. Eliseenkova, A. Yayon, C. Basilico, R. J. Linhardt, J. Schlessinger, and M. Mohammadi. 2004. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. *Proc Natl Acad Sci U S A* 101: 935-940.
146. Loo, B. M., J. Kreuger, M. Jalkanen, U. Lindahl, and M. Salmivirta. 2001. Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. *J Biol Chem* 276: 16868-16876.
147. Jones, A. L., I. K. Poon, M. D. Hulett, and C. R. Parish. 2005. Histidine-rich glycoprotein specifically binds to necrotic cells via its amino-terminal domain and facilitates necrotic cell phagocytosis. *J Biol Chem* 280: 35733-35741.
148. Weisgraber, K. H., S. C. Rall, Jr., R. W. Mahley, R. W. Milne, Y. L. Marcel, and J. T. Sparrow. 1986. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. *J Biol Chem* 261: 2068-2076.
149. Ma, Y., H. E. Henderson, M. S. Liu, H. Zhang, I. J. Forsythe, I. Clarke-Lewis, M. R. Hayden, and J. D. Brunzell. 1994. Mutagenesis in four candidate heparin binding regions (residues 279-282, 291-304, 390-393, and 439-448) and identification of residues affecting heparin binding of human lipoprotein lipase. *J Lipid Res* 35: 2049-2059.
150. Norgard-Sumnicht, K. E., N. M. Varki, and A. Varki. 1993. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. *Science* 261: 480-483.
151. Koenig, A., K. Norgard-Sumnicht, R. Linhardt, and A. Varki. 1998. Differential interactions of heparin and heparan sulfate glycosaminoglycans

- with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. *J Clin Invest* 101: 877-889.
152. Jang, J. H., J. H. Hwang, C. P. Chung, and P. H. Choung. 2004. Identification and kinetics analysis of a novel heparin-binding site (KEDK) in human tenascin-C. *J Biol Chem* 279: 25562-25566.
 153. Yu, H., E. M. Munoz, R. E. Edens, and R. J. Linhardt. 2005. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. *Biochim Biophys Acta* 1726: 168-176.
 154. Sahu, A., and M. K. Pangburn. 1993. Identification of multiple sites of interaction between heparin and the complement system. *Mol Immunol* 30: 679-684.

Figure 1. Heparan sulfate chains are extensively modified. Biosynthesis of heparan sulfate begins by attachment of a tetrasaccharide linkage region to the core protein (e.g. syndecan, glypican) and elongation of the polysaccharide backbone by alternate additions of glucuronic acid and N-acetylglucosamine residues by the EXT and EXTL enzymes. This is followed by N-deacetylation and N-sulfation of N-acetylglucosamine residues by the NDST enzymes, and epimerization of some glucuronic acid residues to iduronic acid by the D-glucuronyl C5-epimerase GLCE. Sulfotransferase enzymes (HS2ST, HS3STs, HS6STs) then add sulfate groups at the 2-O-, 3-O-, and 6-O- positions of the sugar ring.



Figure 2. Heparan sulfate plays several roles in local acute inflammation. HS on the vascular endothelium binds chemokines and thus facilitates their oligomerization and presentation to circulating leukocytes, prevents them being washed away by the


blood flow, and forms the chemokine gradient necessary for directional migration of leukocytes. Endothelial HS may also directly regulate the recruitment of leukocytes by acting as a ligand for leukocyte L-selectin, or by masking other adhesion molecules on the vascular endothelium to make them less accessible to leukocyte integrins. HS also functions in the extracellular matrix (ECM) to retain cytokines and growth factors. This interaction with HS can regulate local signaling by promoting or inhibiting receptor-ligand interactions, and can protect cytokines from inactivation by proteases. The core protein of the HSPG can be cleaved by the proteases released during an inflammatory response to release the ectodomain and its HS chains from the cell surface. Heparanase can digest the HS chains to release small active fragments that can act as danger-associated molecular patterns (DAMPs), or continue to regulate the activity of HS-bound cytokines through acting as a co-receptor (promotes signaling) or a decoy receptor (inhibits signaling).

Figure 3. Leukocyte HS plays many roles in immune regulation. Heparan sulfate proteoglycans facilitate uptake of late apoptotic and necrotic cells, although the mechanism remains unclear. Soluble fragments of HS released during tissue inflammation activate cells through TLR4. HS chains on leukocyte membrane proteins can promote or inhibit receptor-ligand interactions for cytokines and growth factors. Cell-surface proteoglycans can also regulate signalling in trans by presenting growth factors such as FGF-2 to target cells.

Table 1. Summary of immune-associated proteins that have been experimentally demonstrated to bind heparin or HS

Growth factors	Chemokines	Cytokines
Bone morphogenetic protein 2 (BMP-2) (93)	C-C motif chemokine 1 (44)	Interleukin-2 (IL-2) (137)
Bone morphogenetic protein 3 (BMP-3) (94)	C-C motif chemokine 2 (117)	Interleukin-3 (IL-3) (138)
Bone morphogenetic protein 4 (BMP-4) (95)	C-C motif chemokine 3 (118)	Interleukin-4 (IL-4) (139)
Bone morphogenetic protein 6 (BMP-6) (100)	C-C motif chemokine 4 (119)	Interleukin-5 (IL-5) (50)
Bone morphogenetic protein 7 (BMP-7) (96)	C-C motif chemokine 5 (120)	Interleukin-6 (IL-6) (48)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) (106)	C-C motif chemokine 7 (121)	Interleukin-7 (IL-7) (49)
Connective tissue growth factor (CCN family member 2) (97)	C-C motif chemokine 8 (122)	Interleukin-10 (IL-10) (78)
Heparin-binding growth factor 1 (HBGF-1) (111)	Eotaxin (C-C motif chemokine 11) (123)	Interleukin-12 subunit beta (IL-12B) (140)
Fibroblast growth factor 3 (FGF-3) (98)	C-C motif chemokine 13 (124)	Interferon gamma (IFN- γ) (46)
Fibroblast growth factor 4 (FGF-4) (99)	C-C motif chemokine 15 (125)	Tumor necrosis factor (TNF- α) (141)
Fibroblast growth factor 5 (FGF-5) (100)	C-C motif chemokine 17 (126)	
Fibroblast growth factor 6 (FGF-6) (101)	C-C motif chemokine 19 (127)	Other immune-associated proteins
Fibroblast growth factor 7 (FGF-7) (93)	C-C motif chemokine 21 (126)	Neutrophil elastase (Elastase-2) (142)
Fibroblast growth factor 8 (FGF-8) (102)	C-C motif chemokine 22 (128)	Basic fibroblast growth factor receptor 1 (FGFR-1) (143)
(Fibroblast growth factor 9 (FGF-9) (103)	C-C motif chemokine 23 (129)	Fibroblast growth factor receptor 2 (FGFR-2) (144)
Fibroblast growth factor 10 (FGF-10) (104)	C-C motif chemokine 24 (130)	Fibroblast growth factor receptor 3 (FGFR-3) (145)
Fibroblast growth factor 12 (FGF-12) (105)	C-C motif chemokine 25 (127)	Fibroblast growth factor receptor 4 (FGFR-4) (146)
Fibroblast growth factor 14 (FGF-14) (105)	C-C motif chemokine 27 (122)	Histidine-rich glycoprotein (HRG) (147)
Fibroblast growth factor 16 (FGF-16) (106)	C-C motif chemokine 28 (127)	Hepatic triacylglycerol lipase (Hepatic lipase) (148)
Fibroblast growth factor 17 (FGF-17) (106)	C-X-C motif chemokine 1 (131)	Lipoprotein lipase (LPL) (149)
Fibroblast growth factor 18 (FGF-18) (106)	C-X-C motif chemokine 2 (132)	L-selectin (Leukocyte adhesion molecule 1) (150)
Fibroblast growth factor 2 (FGF-2) (107)	C-X-C motif chemokine 4 (Platelet factor 4) (133)	P-selectin (151)
Fibroblast growth factor 20 (FGF-20) (108)	C-X-C motif chemokine 6 (134)	Tenascin-C (152)
Fibroblast growth factor 22 (FGF-22) (106)	C-X-C motif chemokine 7 (131)	
Proheparin-binding EGF-like growth factor (109)	C-X-C motif chemokine 8 (Interleukin-8; IL-8) (131)	
Platelet-derived growth factor subunit A (PDGF-1) (110)	C-X-C motif chemokine 10 (135)	
Platelet-derived growth factor subunit B (PDGF-2) (111)	C-X-C motif chemokine 11 (136)	
Placenta growth factor (PlGF) (108)	C-X-C motif chemokine 13 (127)	
Vascular endothelial growth factor A (VEGF-A) (112)	C-X-C motif chemokine 16 (127)	
Vascular endothelial growth factor B (VEGF-B) (113)		
Transforming growth factor beta-1 (TGF-beta-1) (114)	Complement factors	
Transforming growth factor beta-2 (TGF-beta-2) (114)	Complement factor B (153)	
Hepatoma-derived growth factor (HDGF) (High mobility group protein 1-like 2) (115)	Complement factor D (154)	
Hepatocyte growth factor (Hepatopoeitin-A) (116)	Complement factor H (153)	
	Complement factor I (153)	
	Complement factor P (properdin) (153)	
	Complement component C5 (153)	
	Complement component C6 (153)	
	Complement component C7 (153)	
	Complement component C8 alpha, beta and gamma chains (153)	
	Complement component C9 (153)	






Phagocytosis
of dead cells

Activation
of TLR4

Regulation of
cell signalling

Presentation
of mediators
to other cells



Homeostasis

Inflammation

